Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 932

1.
2.
4.

Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.

Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA.

J Clin Virol. 1999 Aug;13(3):149-59.

PMID:
10443791
5.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
6.

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.

Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.

Transpl Infect Dis. 2000 Sep;2(3):112-7.

PMID:
11429021
7.

Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.

Turgeon N, Fishman JA, Doran M, Basgoz N, Tolkoff-Rubin NE, Cosimi AB, Rubin RH.

Transpl Infect Dis. 2000 Mar;2(1):2-10.

PMID:
11429003
8.
10.

Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.

Ginevri F, Losurdo G, Fontana I, Rabagliati AM, Bonatto L, Valente R, Venzano P, Nocera A, Basile GC, Valente U, Gusmano R.

Transpl Int. 1998;11 Suppl 1:S130-4.

11.

New developments in the management of cytomegalovirus infection after solid organ transplantation.

Eid AJ, Razonable RR.

Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000. Review.

PMID:
20481654
12.

Cytomegalovirus infection after liver transplantation: current concepts and challenges.

Razonable RR.

World J Gastroenterol. 2008 Aug 21;14(31):4849-60. Review.

13.

Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.

Murray BM, Subramaniam S.

Transpl Infect Dis. 2004 Mar;6(1):3-9.

PMID:
15225220
14.

Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.

Varga M, Remport A, Hídvégi M, Péter A, Kóbori L, Telkes G, Fazakas J, Gerlei Z, Sárváry E, Sulyok B, Járay J.

Transpl Infect Dis. 2005 Jun;7(2):63-7.

PMID:
16150092
15.

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.

Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.

Transplantation. 1997 Jul 15;64(1):66-73.

PMID:
9233703
16.
17.

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.

Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, Webster A; Valacyclovir International Bone Marrow Transplant Study Group.

Blood. 2002 Apr 15;99(8):3050-6.

18.

Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.

Bone Marrow Transplant. 1996 Apr;17(4):589-93.

PMID:
8722360
20.

Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.

Tsinontides AC, Bechtel TP.

Ann Pharmacother. 1996 Nov;30(11):1277-90. Review.

PMID:
8913411

Supplemental Content

Support Center